Drug Management of Prostate Cancer / Edition 1

by William D. Figg, Cindy H. Chau, Eric J. Small

Overview

Prostate cancer is the most common noncutaneous prostate cancer. Research has revealed several distinct malignancy and the second leading cause of cancer mechanisms of castration-resistant disease that may deaths among men in the United States. It is a critical converge in patients with disease progression on public health problem and remains incurable in the ADT. Many approaches are currently being evaluated metastatic setting with mortality that usually occurs as to improve the treatment of this condition and these a result of castration-resistant disease. fndings have identifed several potential targets for Since Huggins and Hodges’ report of the dra- therapeutic intervention. These include drugs that are matic clinical effects of suppressing serum testos- more active or less toxic chemotherapy agents; drugs terone levels in men with advanced prostate cancer that induce androgen deprivation; drugs that target in 1941, hormone therapy (also called androgen the androgen receptor and/or androgen synthesis; deprivation therapy [ADT]) has become widely drugs that target specifc pathways, including ang- accepted as the mainstay of therapy for the treat- genesis and tyrosine kinase inhibitors, endothelin ment of advanced prostate cancer. ADT combined antagonists and matrix metalloproteinase inhibitors; with radiation therapy is a standard of care in the and immunologic approaches. Many of these agents treatment of men with locally advanced prostate seem promising and the rationale and effcacy of cancer on the basis of evidence that shows improved these emerging therapies remain to be validated in survival. The role of ADT in the management of future clinical trials.

Product Details

ISBN-13:	9781603278317
Publisher:	Springer New York
Publication date:	09/17/2010
Edition description:	2010
Pages:	430
Product dimensions:	7.48(w) x 10.24(h) x 0.05(d)

Table of Contents

Section One Hormone Therapy Chapter 1 Cell Biology of Prostate Cancer and Molecular Targets Martin E. Gleave, Michael E. Cox, Yuzhuo Wang Chapter 2 Luteinizing Hormone-Releasing Hormone (Lh-Rh) and its Agnostic, Antagonistic and Targeted Cytotoxic Analogs in Prostate Cancer Andrew V. Schally and Norman L. Block Chapter 3 Nuclear Receptor Coregulators: Promising Therapeutic Targets for the Treatment of Prostate Cancer Hannelore V. Heemers and Donald J. Tindall Chapter 4 Androgens and Prostate Cancer Douglas K. Price and Ann W. Hsing Chapter 5 Androgen Receptor Biology in Prostate Cancer Edward P. Gelmann Chapter 6 Androgen Receptor Antagonists Howard C. Shen, Mary-Ellen Taplin, Steven P. Balk Chapter 7 5 alpha Reductase Inhibitors in Prostate Cancer Zoran Culig Chapter 8 Adrenolytic Therapies in Castration Resistant Prostate Cancer Terence W. Friedlander and Charles J. Ryan Chapter 9 Androgen Deprivation Therapy Nima Sharifi Chapter 10 Pharmacogenetics of the Androgen Metabolic Pathway Francine Zanchetta Coehlo Marques and Juergen Reichardt Section Two Chemotherapy Chapter 11 Mitoxantrone Patricia Halterman, Nicholas J. Vogelzang, Alireza Farabishahadel, Oscar B. Goodman, Jr. Chapter 12 Docetaxel Courtney K. Phillips and Daniel P. Petrylak Chapter 13 Beyond Docetaxel: Emerging Agents in the Treatment of Advanced Prostate Cancer Jonathan Rosenberg Chapter 14 Platinum Agents in Prostate Cancer Ashley Brick, Junyang Niu, Jiaoti Huang, William K. Oh Chapter 15 Clinical Pharmacology and Pharmacogenetics of Chemotherapy in Prostate Cancer Tristan M. Sissung and William D. Figg Chapter 16 Microtubule Targeting Agents Antonio Tito Fojo and David E. Adelberg Section Three Angiogenesis Chapter 17 Principles of Antiangiogenic Therapy Cindy H. Chau and William D. Figg Chapter 18 Bevacizumab in Advanced Prostate Cancer Aymen A. Elfiky and William Kevin Kelly Chapter 19 Thalidomide and Analogs Erin R. Gardner, Giuseppe Di Lorenzo, and William D. Figg Chapter 20 Investigational Angiogenesis Inhibitors Jeanny B. Aragon-Ching, William Dahut, MD Chapter 21 Pharmacogenetics of Angiogenesis Guido Bocci, Giuseppe Pasqualetti, Antonello Di Paolo, Francesco Crea, Mario Del Tacca, Romano Danesi Section Four Bone Metastasis Chapter 22 Pathophysiology of Prostate Cancer Bone Metastasis Evan T. Keller and Christopher L. Hall Chapter 23 Radiopharmaceuticals Oliver Sartor and Damerla R. Venugopal Chapter 24 Bisphosphonates for Prevention and Treatment of Bone Metastases Philip J. Saylor and Matthew R. Smith Chapter 25 Endothelin Receptors as Therapeutic Targets in Castrate Resistant Prostate Cancer Joel B. Nelson Chapter 26 Calcitriol and Vitamin D Analogs Ana R. Jensen, Russell Z. Szmulewitz, Tomasz M. Beer, Edwin M. Posadas Chapter 27 Cancer Immunology, Immunotherapeutics and Vaccine Approaches Ravi A. Madan, James L. Gulley, Jackie Celestin, Philip M. Arlen, Jeffrey Schlom Chapter 28 Sipuleucel-T (APC8015): Active Cellular Immunotherapy for Advanced Metastatic Castrate-Resistant Prostate Cancer Celestia S. Higano and Mark W. Frohlich Chapter 29 GM-CSF Genes Transduced Prostate Cancer Vaccines: GVAX Lalit R. Patel and Jonathan W. Simons Chapter 30 CTLA-4 Blockade for Prostate Cancer Treatment Andrea L. Harzstark and Lawrence Fong Section Five – Prevention Chapter 31 Prostate Cancer Chemoprevention Strategies Howard L. Parnes, Margaret G. House, Joseph A. Tangrea Chapter 32 Diet and Prostate Cancer Incidence, Recurrence, and Progression Risk June M. Chan and Erin L. Richman Chapter 33 Inflammation as a Target in Prostate Cancer Marshall Scott Lucia, James R. Lambert, Elizabeth A. Platz, Angelo M. De Marzo Section Six Drug Development Chapter 34 Challenges for the Development of New Agents in Prostate Cancer Ajjai S. Alva, Deborah A. Bradley, Maha Hussain Chapter 35 FDA Approval of Prostate Cancer

Editorial Reviews

Reviewer: Jianqing Lin, MD (Thomas Jefferson University)
Description: The 36 chapters in this book, written by well-known experts in various aspects of prostate cancer epidemiology, biology, pharmacology, immunology, pathology, drug development, and clinical trials, read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer.
Purpose: This is an excellent overview of the opportunities and challenges in the drug management of prostate cancer to optimize patients' survival and quality of life. While presenting the viewpoints of various experts, the book also covers current standard and investigational treatment options. It is a valuable and up-to-date resource for both basic scientists and clinicians, as the field has been fast evolving in recent years.
Audience: As a comprehensive, concise summary of the pharmacological treatments of prostate cancer, both conventional and emerging, this book is suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry.
Features: The book is divided into seven sections, preceded by an introduction that discusses the cell biology and molecular targets of prostate cancer. Part I describes the role of androgens and androgen deprivation therapy in prostate cancer, and several types of hormone therapy used to treat advanced prostate cancer, including luteinizing hormone-releasing hormone agonists and antagonists. Androgen receptor biology and the pharmacogenetics of the androgen metabolic pathway are also examined. Part II discusses the role of chemotherapy in prostate cancer and covers standard and investigational approaches as well as the clinical pharmacology and pharmacogenetics of these agents. Part III discusses angiogenesis in prostate cancer as a novel target of intervention, principles of antigenic therapy and investigational angiogenesis inhibitors, and pharmacogenetics of angiogenesis. Part IV focuses on the pathophysiology of prostate cancer bone metastasis and agents used at this stage of the disease, a common process of castrate-resistant prostate cancer. Part V presents the immunotherapeutic and vaccine approaches, a very promising noncytotoxic treatment option for a disease with a long natural history. Part VI discusses chemoprevention strategies and part VII presents the challenges for drug development in prostate cancer. An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference.
Assessment: The chapters in this book are well written and provide material for objective discussions of the various topics. This is an excellent resource for readers interested in the management of advanced prostate cancer, as well as controversies and modern advances.

Doody's Review Service

From the reviews:

“For medical oncologists, trainees, researchers, and those in the pharmaceutical industry, Figg … offer a comprehensive and concise summary of the pharmacological treatments for prostate cancer, both current standard and investigative options. The 36 chapters … focus on a multidisciplinary care approach and cover hormone therapy, chemotherapy, angiogenesis, therapy for bones metastases, immunotherapy, chemoprevention, and drug development. Cell biology and molecular targets are also discussed.” (SciTech Book News, December, 2010)

“The 36 chapters in this book … read as independent discussions of many of the most recent discoveries in the area of drug management of prostate cancer. … suitable for medical students, physicians in training, physicians (especially medical oncologists), scientists, translational researchers, and members of the pharmaceutical industry. … An important aspect of this book is that the data represents updated, state-of-the-art information, making it valuable for daily reference. … an excellent resource for readers interested in the management of advanced prostate cancer … .” (Jianqing Lin, Doody’s Review Service, December, 2010)

“This treatise is an exhaustive description of the application of drug management of prostate cancer involving both standard care and investigational agents. … this book will give the reader a detailed insight about the current knowledge from clinical trials into the drug treatment of prostate tumours. The urologists, medical oncologist and others involved in the treatment of the prostate cancer will find in this work a complete review of where we are now.” (M. Horňák, Neoplasma, March, 2011)

“This textbook by W.D. Figg and co-authors … makes an exhaustive overview of present and future medical therapies of prostate cancer. … This book provides the reader with comprehensive information about pharmacological treatments of prostate cancer. All chapters are concise and most of them are well-illustrated. We recommend this textbook to urologists, oncologists who are involved in prostate cancer management, and to all physicians and students who want to update their knowledge in prostate cancer management.” (European Urology Today, April/May, 2011)

From the Publisher